Search research articles
Contact Us
Filters
Showing results (51-60 of 96) with videos related to
Page
of 10
Sort By:
Clinical Pharmacokinetics
|
January 24, 2021
Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease
Dinko Rekić, Virginie Kerbusch-Herben, Mats Någård, et al.
European Journal of Medicinal Chemistry
|
January 15, 2024
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells
Kairui Yue, Simin Sun, Enqiang Liu, et al.
Bioorganic Chemistry
|
March 21, 2020
Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation
Ana Xu, Feng He, Xiangna Zhang, et al.
Experimental Eye Research
|
April 10, 2016
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities
Jie Fan, Oday Alsarraf, C James Chou, et al.
Plos One
|
January 26, 2010
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model
Myriam Rai, Elisabetta Soragni, C James Chou, et al.
Journal of Medicinal Chemistry
|
July 31, 2015
Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor
Wenwen Duan, Jin Li, Elizabeth S Inks, et al.
The Journal of Biological Chemistry
|
October 1, 2004
Functional studies of the Mycobacterium tuberculosis iron-dependent regulator
C James Chou, Goragot Wisedchaisri, Ryan R Monfeli, et al.
Journal of Medicinal Chemistry
|
April 4, 2014
Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity
Xiaoyang Li, Elizabeth S Inks, Xiaoguang Li, et al.
Journal of Medicinal Chemistry
|
April 24, 2015
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor
Wenwen Duan, Jin Li, Elizabeth S Inks, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
Xiaoyang Li, Yuri K Peterson, Elizabeth S Inks, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 96) with videos related to
Sort By:
Page
of 10
Clinical Pharmacokinetics
|
January 24, 2021
Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease
Dinko Rekić, Virginie Kerbusch-Herben, Mats Någård, et al.
European Journal of Medicinal Chemistry
|
January 15, 2024
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells
Kairui Yue, Simin Sun, Enqiang Liu, et al.
Bioorganic Chemistry
|
March 21, 2020
Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation
Ana Xu, Feng He, Xiangna Zhang, et al.
Experimental Eye Research
|
April 10, 2016
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities
Jie Fan, Oday Alsarraf, C James Chou, et al.
Plos One
|
January 26, 2010
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model
Myriam Rai, Elisabetta Soragni, C James Chou, et al.
Journal of Medicinal Chemistry
|
July 31, 2015
Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor
Wenwen Duan, Jin Li, Elizabeth S Inks, et al.
The Journal of Biological Chemistry
|
October 1, 2004
Functional studies of the Mycobacterium tuberculosis iron-dependent regulator
C James Chou, Goragot Wisedchaisri, Ryan R Monfeli, et al.
Journal of Medicinal Chemistry
|
April 4, 2014
Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity
Xiaoyang Li, Elizabeth S Inks, Xiaoguang Li, et al.
Journal of Medicinal Chemistry
|
April 24, 2015
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor
Wenwen Duan, Jin Li, Elizabeth S Inks, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
Xiaoyang Li, Yuri K Peterson, Elizabeth S Inks, et al.
Page
of 10